Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) Director Sells 3,650 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Rita Balice-Gordon sold 3,650 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded down $0.88 during mid-day trading on Tuesday, reaching $47.03. The company had a trading volume of 902,501 shares, compared to its average volume of 399,640. The company has a 50-day moving average price of $39.62 and a two-hundred day moving average price of $35.49. The stock has a market cap of $1.49 billion, a PE ratio of 29.21 and a beta of 0.61. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $49.09.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business had revenue of $135.55 million during the quarter. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. grew its stake in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares in the last quarter. CWM LLC raised its holdings in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 368.9% in the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,169 shares during the period.

Wall Street Analyst Weigh In

COLL has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings raised shares of Collegium Pharmaceutical from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 21st. Truist Financial increased their target price on Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, HC Wainwright raised their target price on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $47.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.